Abstract Library

#4115 Neoadjuvant PRRT with 90Y-DOTATOC: Preliminary results from a monocentric perspective study

Introduction: Surgery is considered the only curative treatment for pancreatic neuroendocrine tumors (pNETs), but it is feasible only in a few patients. A new possible strategy in pNETs is preoperative PRRT, as its cytoreductive effect could increase the efficacy of surgery.

Conference:

Presenting Author:

Authors: Barone A, Grana C, Papi S, Bertani E, Rocca P,

Keywords: PRRT, 90Y-DOTATOC, Neoadjuvant PRRT, pancreatic NET,

#3707 Neoadjuvant PRRT with Y-90-DOTATOC – Preliminary results from a monocentric prospective study

Introduction: Surgery is considered the only curative option in pNET but is feasible only in a minority of patients. A new possible therapeutical strategy in pNETs is preoperative Peptide Receptor Radionuclide Therapy (PRRT) in order to increase the efficacy of surgery.

Conference:

Presenting Author: Grana C

Authors: Grana C, Papi S, Bertani E, Cascio A, Rocca P,

Keywords: PRRT, Y-90-Dotatoc, Neoadjuvant PRRT, pancreatic NET,

#3705 First results from IEO 676 clinical study of PRRT in neuroendocrine tumors – Is there still a space for Y-90-DOTATOC?

Introduction: IEO 676 is a prospective phase II study of Peptide Receptor Radionuclide Therapy (PRRT) with Y-90-DOTATOC in progressive G1, G2, G3, neuroendocrine patients. PRRT has been in use since the late 1990s, with the introduction of 90Y-DOTATOC, which allowed objective responses in 10-30% of treated patients.

Conference:

Presenting Author: Grana C

Authors: Grana C, Papi S, Clerici I, Rocca P, Spada F,

Keywords: PRRT, Y-90-DOTATOC, NET,

#3670 Response to peptide receptor radionuclide therapy in pheochromocytomas and paragangliomas – A systematic review and meta-analysis

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC has shown efficacy in the metastatic setting of pheochromocytomas (PCCs) and paragangliomas (PGLs) where no standard therapies have been established.

Conference:

Presenting Author: Marretta A

Authors: Marretta A, Ottaiano A, Iervolino D, Bracigliano A, Clemente O,

Keywords: PRRT, Pheochromocytoma, Paraganglioma, Neuroendocrine Tumor, Meta-analysis,

#3491 Renal uptake monitoring during different cycles of 90Y-DOTATOC therapy based on 111In and 90Y SPECT imaging

Introduction: Unresectable or borderline resectable WHO G1/G2 P-NETs patients with limited liver disease are treated with 6 90Y-DOTATOC therapy cycles within a clinical protocol. Kidney dosimetry is performed at first cycle. Assuming equal absorbed dose for all cycles, cycles are reduced if cumulative dose exceeds kidney toxicity limits.

Conference:

Presenting Author: d'Arcangelo M

Authors: d'Arcangelo M, Botta F, Ferrari M, Ghisini R, Fodor C,

Keywords: dosimetry, PRRT, 90Y,